102.38 USD
↗ 1.14 (1.13%)AT CLOSE (11:59 AM EDT)
Incyte Genomics Inc
INCYNASDAQ • USD
101.20
↘ 1.18 (1.15%)
POST MARKET (AS OF 07:45 PM EDT)
Post Market
AS OF 07:45 PM EDT
101.20
↘ 1.18 (1.15%)
Market: CLOSED
Open?$101.19
High?$106.37
Low?$100.81
Prev. Close?$101.24
Volume?2.6M
Avg. Volume?1.5M
VWAP?$103.99
Rel. Volume?1.72x
Bid / Ask
Bid?$97.93 × 100
Ask?$108.96 × 100
Spread?$11.03
Midpoint?$103.45
Valuation & Ratios
Market Cap?20.5B
Shares Out?199.8M
Float?166.2M
Float %?83.5%
P/E Ratio?14.29
P/B Ratio?3.64
EPS?$7.17
Dividend?0.00%
Ex-Dividend?N/A
INCY is currently priced at $102.38. The stock presents a bullish profile across the board: both technical indicators and our fundamental models signal a "Strong Buy" and "Buy" respectively. This is driven by a robust Altman Z-Score, exceptional Return on Equity (25.5%), a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics suggest INCY is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Jun 5, 2026.
RelatedABBV
News
Profile
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Themes
Employees
2.8K
Market Cap
20.5B
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Website
Listed
1993-11-03
Address
1801 AUGUSTINE CUT-OFF
WILMINGTON, DE 19803
Phone: (302) 498-6700
WILMINGTON, DE 19803
Phone: (302) 498-6700
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?60
Z-Score?100
Momentum?73
Short Sent.?63
Piotroski F-Score?5/9Mixed
Altman Z-Score?17.79Safe
Confidence?73%Moderate
Short InterestHigh
Short % of Float?6.64%Elevated
Short Interest?11.0M
Days to Cover?8.7
Free Float166.2M
Avg Daily Volume1.3M
Settlement Date2026-05-15
Financial Health
Current Ratio?3.68Strong
Quick Ratio?3.60Strong
Cash Ratio?2.32Strong
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?14.3CHEAP▾
Peers100
S&P83
P/B?3.64FAIR▾
S&P48
P/S?3.82FAIR▾
Peers100
S&P40
P/FCF?14.1CHEAP▾
Peers100
S&P77
EV/EBITDA?11.0CHEAP▾
Peers100
S&P74
EV/Sales?3.18FAIR▾
Peers100
S&P58
Returns & Efficiency
ROE?25.5%STRONG▾
S&P75
ROA?19.5%STRONG▾
Peers100
S&P95
Cash Flow & Enterprise
FCF?$1.5B
Enterprise Value?$17.0B
Fundamentals ratios updated end of day